UK clinical trial reforms are accelerating timelines—without reducing accountability. Learn how inspection readiness and documentation expectations are evolving.
In 2025, several major pharmaceutical companies — including MSD (Merck), AstraZeneca, and Eli Lilly — have scaled back or cancelled planned investments in the UK. Decisions have ranged from pausing vaccine-manufacturing expansions to abandoning research center projects.